文献速递肥胖与代谢综合征糖尿病

PPP1R3B附近非编码变异促进肝糖原储存与代谢综合征但降低心肌梗死风险

A Noncoding Variant Near PPP1R3B Promotes Liver Glycogen Storage and MetS, but Protects Against Myocardial Infarction.
PubMed 文献 · J Clin Endocrinol Metab · 2021-01-01

该研究基于人群队列,探讨rs4841132-A(频率2%-19%)与肝脏衰减的关联及功能。携带者肝糖原沉积增加而非脂肪变,rs4841132-A通过顺式作用增加PPP1R3B、降低LOC157273。该变异与代谢综合征全部组分相关,却与低密度脂蛋白胆固醇降低及心肌梗死风险降低相关。

要点

  • rs4841132-A携带者肝脏衰减增加提示糖原沉积,而非肝脂肪变。
  • 该变异经顺式调控增加PPP1R3B并降低LOC157273,促进肝糖原累积。
  • 该变异促进代谢综合征但降低LDL胆固醇和心肌梗死风险。

核心结论

  • rs4841132-A通过增加PPP1R3B和降低LOC157273促进肝糖原储存病,推动代谢综合征发展,但降低LDL胆固醇和心肌梗死风险。
  • 肝糖原升高可能是代谢综合征的原因之一,但不一定促进心肌梗死。

研究设计与样本

  • 研究来自肥胖相关肝病遗传学联盟,为基于人群的设计,主要结局为计算机断层扫描测量的肝脏衰减。

主要发现

  • rs4841132-A携带者频率为2%-19%,无肝脂肪变增加,但肝脏衰减增加提示糖原沉积增加。
  • rs4841132位于非编码RNA LOC157273内,距PPP1R3B上游约190 kb,rs4841132-A通过顺式遗传效应增加PPP1R3B。
  • 在人类肝癌细胞中利用CRISPR/Cas9构建包含rs4841132-A的105 bp缺失,可增加PPP1R3B、降低LOC157273并增加糖原,完美模拟人类疾病。
  • 基于电子健康记录数据,rs4841132-A与代谢综合征所有组分相关,但与LDL胆固醇降低及心肌梗死风险降低相关。
  • rs4841132-A的代谢特征包括甘氨酸、乳酸、甘油三酯升高,乙酰乙酸和β-羟丁酸降低。

临床怎么用

  • 认识rs4841132-A携带者肝衰减增加反映糖原沉积而非脂肪变,避免误判为脂肪肝。
  • 该变异提示代谢综合征组分聚集但心肌梗死风险降低,需综合评估心血管风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Glycogen storage diseases are rare. Increased glycogen in the liver results in increased attenuation. OBJECTIVE: Investigate the association and function of a noncoding region associated with liver attenuation but not histologic nonalcoholic fatty liver disease. DESIGN: Genetics of Obesity-associated Liver Disease Consortium. SETTING: Population-based. MAIN OUTCOME: Computed tomography measured liver attenuation. RESULTS: Carriers of rs4841132-A (frequency 2%-19%) do not show increased hepatic steatosis; they have increased liver attenuation indicative of increased glycogen deposition. rs4841132 falls in a noncoding RNA LOC157273 ~190 kb upstream of PPP1R3B. We demonstrate that rs4841132-A increases PPP1R3B through a cis genetic effect. Using CRISPR/Cas9 we engineered a 105-bp deletion including rs4841132-A in human hepatocarcinoma cells that increases PPP1R3B, decreases LOC157273, and increases glycogen perfectly mirroring the human disease. Overexpression of PPP1R3B or knockdown of LOC157273 increased glycogen but did not result in decreased LOC157273 or increased PPP1R3B, respectively, suggesting that the effects may not all occur via affecting RNA levels. Based on electronic health record (EHR) data, rs4841132-A associates with all components of the metabolic syndrome (MetS). However, rs4841132-A associated with decreased low-density lipoprotein (LDL) cholesterol and risk for myocardial infarction (MI). A metabolic signature for rs4841132-A includes increased glycine, lactate, triglycerides, and decreased acetoacetate and beta-hydroxybutyrate. CONCLUSIONS: These results show that rs4841132-A promotes a hepatic glycogen storage disease by increasing PPP1R3B and decreasing LOC157273. rs4841132-A promotes glycogen accumulation and development of MetS but lowers LDL cholesterol and risk for MI. These results suggest that elevated hepatic glycogen is one cause of MetS that does not invariably promote MI.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Kahali B, Chen Y, Feitosa MF, et al. A Noncoding Variant Near PPP1R3B Promotes Liver Glycogen Storage and MetS, but Protects Against Myocardial Infarction. J Clin Endocrinol Metab. 2021. PMID: 33231259. doi:10.1210/clinem/dgaa855

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。